For most medicines, it doesn't matter when you take them. But others work best at particular times.
There's a big market for new treatments for TB, malaria and other ailments. But most of these diseases afflict low-income people unable to pay for medicine.
While critics accuse companies facing lots of lawsuits of using bankruptcy as a sort of 'get of jail free card,' the reality of the legal procedure is more complicated.
Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
The first study to assess the carbon footprint of the pharmaceutical industry finds that it is far from green.
American companies still face enormous uncertainty about how they'll be doing business in the UK and EU in the coming years, particularly as the April 12 Brexit deadline draws closer.
A new agency and money for drugs for rare diseases are only very partial steps on the road towards what Canada really needs: a national pharmacare plan.
OxyContin maker Purdue has reportedly been mulling a bankruptcy filling, just as the first of around 2,000 lawsuits against it prepares to go to trial.
The Trump administration's proposal to lower drug prices focuses on discounts. A health policy scholar argues that the US could learn from Europe's system of measuring drug value and effectiveness.
Clinical guidelines have a big impact on the care you receive and the drugs you're prescribed. But one in five doctors who write these guidelines have undisclosed ties to drug companies.
Don't mix your statins with grapefruit, or leafy green vegetables with warfarin.
Pharmaceuticals were found in every invertebrate sampled from six Melbourne streams - including a waterway in a national park.
A new book, 'The Thalidomide Catastrophe,' raises new questions about the conduct of corporations involved. It is the duty of governments to find out the answers.
Drug trials should include people with more than one disease.
Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
Could issues like price manipulation and over-regulation be having an impact on the medicine supply chain?
In the run up to the Global Hepatitis Summit 2018, new guidelines for the management of hepatitis C should come under scrutiny – for financial conflict of interest and quality of evidence.
Medical cannabis challenges scientific norms and the usual regulation of medicines.
Researchers who've created a kidney-on-a-chip explain why these kinds of devices are an improvement over traditional ways to test new drugs.
Prescription drugs are policed by industry and Health Canada has never prosecuted a drug company for illegally marketing a drug.